3名固体生物科学内部人员在2026年2月4日出售了280多万美元的库存,因为该公司报告了损失和损失的收入。 Three Solid Biosciences insiders sold over $280K in stock on Feb. 4, 2026, as the company reported a loss and missed earnings.

2月4日, 2026年2月4日, Gabriel Brooks、Jessie Hanrahan 和David Howton三家固体生物科学公司内幕人士共出售43 858股股票,平均价为6.44美元,共约282 445美元。 On February 4, 2026, three insiders at Solid Biosciences—Gabriel Brooks, Jessie Hanrahan, and David Howton—sold a combined total of 43,858 shares at an average price of $6.44, totaling approximately $282,445. 这些交易降低了各自的股份,与布鲁克斯、汉拉汉和豪顿分别分别向证交会分别申报出售股票。 The transactions reduced their respective stakes, with Brooks, Hanrahan, and Howton each selling shares in separate filings with the SEC. 该公司报告的季度损失为每股0.48美元,缺损估计数,分析家预测全年损失为2.84美元。 The company reported a quarterly loss of $0.48 per share, missing estimates, and analysts project a full-year loss of $2.84. 固体生物科学是一种临床阶段的生物技术,为Duchenne肌肉萎缩症开发基因疗法,其市场上限为5.0797亿美元,协商一致的“Moderate Buy”评级为14.70美元,目标价格为14.70美元。 Solid Biosciences, a clinical-stage biotech developing a gene therapy for Duchenne muscular dystrophy, has a market cap of $507.97 million and a consensus “Moderate Buy” rating with a target price of $14.70.